GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (FRA:1VT) » Definitions » Stock Based Compensation

Viking Therapeutics (FRA:1VT) Stock Based Compensation : €30.58 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Stock Based Compensation?

Viking Therapeutics's Stock Based Compensation for the three months ended in Mar. 2025 was €10.50 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was €30.58 Mil.


Viking Therapeutics Stock Based Compensation Historical Data

The historical data trend for Viking Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Stock Based Compensation Chart

Viking Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.78 5.40 8.19 15.36 28.38

Viking Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.34 6.58 8.09 5.41 10.50

Viking Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €30.58 Mil.


Viking Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Viking Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Headlines

No Headlines